Shorter antibiotic courses (as short as 3-7 days for most common infections) combined with extended or continuous infusion beta-lactams in the ICU represent the two highest-impact antimicrobial stewardship interventions available to pharmacists today.
Key Results
BALANCE trial (N=3,631): 7 vs 14 days for gram-negative bacteremia was non-inferior for 90-day mortality (difference -1.6%, 95% CI -4.0 to 0.8) with 5 more antibiotic-free days. BLING III (N=7,202): Continuous infusion beta-lactams showed clinical cure 55.7% vs 50.0% (p<0.001). JAMA Bayesian meta-analysis (N=9,108, 18 RCTs): mortality RR 0.86 (95% CrI 0.72-0.98) with 99.1% posterior probability of benefit.
Clinical Interpretation
The evidence for shorter antibiotic courses is now overwhelming for most common infections including CAP (3-5 days), gram-negative bacteremia (7 days), intra-abdominal infections with source control (4 days), and bone/joint infections (IV-to-PO switch after 1 week). Extended/continuous infusion beta-lactams maximize time above MIC in critically ill patients, with the JAMA meta-analysis providing high-certainty evidence of mortality benefit.
Pharmacist Action Items
At every antimicrobial assessment, perform a dual intervention: duration check (can this course be shortened?) and infusion optimization (should this beta-lactam be extended/continuous?).
Document target stop dates at antibiotic initiation to prevent default prolonged courses.
For ICU patients on piperacillin-tazobactam or meropenem, recommend conversion to extended (3-4h) or continuous (24h) infusion with appropriate loading doses.
Know the exceptions: S. aureus bacteremia (minimum 14 days), endocarditis (4-6 weeks), undrained sources, and immunocompromised patients are NOT candidates for short-course therapy.
Address meropenem stability for continuous infusion: room temperature stability is ~8 hours, requiring q8h bag changes or ice jacket systems. Extended 3-hour infusion is often more practical.
Champion IV-to-PO conversion using high-bioavailability oral agents (fluoroquinolones, rifampin, linezolid) based on OVIVA trial evidence.
Oral step-down after 1 week IV is non-inferior for bone/joint infections
Evidence-Based Antibiotic Duration
Infection
Traditional
Evidence_based
Key_evidence
Community-acquired pneumonia
7-14 days
3-5 days
ATS/IDSA 2019; Annals IM 2026 (PMID 41974005)
HAP/VAP
14-21 days
7 days
ATS/IDSA 2016
Gram-negative bacteremia
14 days
7 days
BALANCE trial (PMID 39565030)
Intra-abdominal (source controlled)
10-14 days
4 days
STOP-IT (PMID 25992746)
Uncomplicated cellulitis
10-14 days
5-6 days
Hepburn 2004 (PMID 15302637)
Complicated UTI/pyelonephritis
10-14 days
5-7 days
IDSA 2025 (PMID 41419448)
Bone and joint infections
6 weeks IV
6 weeks (IV to early PO switch)
OVIVA (PMID 30699315)
Important Exceptions
S. aureus bacteremia (minimum 14 days).
Endocarditis (4-6 weeks).
Undrained/uncontrolled source.
Immunocompromised patients.
Prosthetic device infections.
Meningitis.
Guideline Context
ATS/IDSA 2019 supports short-course CAP therapy. IDSA 2025 cUTI guideline explicitly recommends shorter courses. Surviving Sepsis Campaign now provides a weak recommendation for prolonged beta-lactam infusion. BALANCE trial (NEJM 2024) is the largest RCT on antibiotic duration for bacteremia.